Heidi Steiner, PSM Awarded ASCPT Presidential Trainee Award
Heidi Steiner, PSM was awarded the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Presidential Trainee Award in recognization for her abstract: "Validity of International Warfarin Pharmacogenetic Consortium (IWPC) Dosing Algorithm and Application of Machine Learning to Predict Warfarin Dose Variability in US Latino and Latin American Populations”.
Dr. Jason H. Karnes, PhD, PharmD, BCPS, FAHA awarded The Jay A. Gandolfi New Investigator Award
The A. Jay Gandolfi New Investigator Award
The A Jay Gandolfi New Investigator Award is awarded to those who make fundamental contributions to the field of Pharmacology, Toxicology, and Environmental Science. The Award recognizes outstanding original research contributions that have a major impact on future research.
PhD Student, Heidi Steiner, PSM awarded Grant Funding
Research and Projects (ReaP) Grant
The Graduate Professional Student Council awarded Heidi Steiner, PSM $1,500 for her PhD project The Warfarin Microbiome Project.
ReaP grants provide funding for academic research projects for graduate and professional students to advance their education.
New paper published in the Journal of Clinical and Translational Science
Abstract
PubMed Article
We conducted a multi‐site investigation of genetic determinants of warfarin dose variability in Latinos from the U.S. and Brazil. Patients from four institutions in the United States (n = 411) and Brazil (n = 663) were genotyped for VKORC1 c.‐1639G> A, common CYP2C9 variants, CYP4F2*3, and NQO1*2. Multiple regression analysis was used in the U.S. cohort to test the association between warfarin dose and genotype, adjusting for clinical factors, with further testing in an independent cohort of Brazilians. In the U.S. cohort, VKORC1 and CYP2C9 variants were associated with lower warfarin dose (β = −0.29, P < 2.0 × 10−16; β = −0.21, P = 4.7 × 10−7, respectively) whereas CYP4F2 and NQO1 variants were associated with higher dose (β = 0.10, P = 2 × 10−4; β = 0.10, P = 0.01, respectively). Associations with VKORC1 (β = −0.14, P = 2.0 × 10−16), CYP2C9 (β = −0.07, P = 5.6 × 10−10), and CYP4F2 (β = 0.03, P = 3 × 10−3), but not NQO1*2 (β = 0.01, P = 0.30), were replicated in the Brazilians, explaining 43–46% of warfarin dose variability among the cohorts from the U.S. and Brazil, respectively. We identified genetic associations with warfarin dose requirements in the largest cohort of ancestrally diverse, warfarin‐treated Latinos from the United States and Brazil to date. We confirmed the association of variants in VKORC1, CYP2C9, and CYP4F2 with warfarin dose in Latinos from the United States and Brazil.
New Paper Published in the American Journal of Respiratory and Critical Care Medicine
Abstract
RATIONALE:
Limited information is available on racial/ethnic differences in pulmonary arterial hypertension (PAH).
OBJECTIVES:
Determine effects of race/ethnicity and ancestry on mortality and disease outcomes in diverse patients with PAH.
METHODS:
Group 1 PAH patients were included from two national registries with genome-wide data and two local cohorts and further incorporated in a global meta-analysis. Hazard ratios (HRs) were calculated for transplant-free all-cause mortality in Hispanics with Non-Hispanic whites (NHWs) as the reference group. Odds ratios (ORs) for inpatient-specific mortality in PAH patients were also calculated for race/ethnic groups from an additional National Inpatient Sample (NIS) dataset, not included in the meta-analysis.
MEASUREMENTS AND MAIN RESULTS:
After covariate adjustment, self-reported Hispanics (n=290) exhibited significantly reduced mortality versus NHWs (n=1970) after global meta-analysis (HR 0.60[0.41-0.87], p=0.008). Although not significant, increasing Native American genetic ancestry appeared to account for part of the observed mortality benefit (HR 0.48[0.23-1.01], p=0.053) in the two national registries. Finally, in the NIS, an inpatient mortality benefit was also observed for Hispanics (n=1524) versus NHWs (n=8829; OR 0.65[0.50-0.84], p=0.001). An inpatient mortality benefit was observed for Native Americans (n=185; OR 0.38[0.15-0.93], p=0.034).
CONCLUSIONS:
This study demonstrates a reproducible survival benefit for Hispanic Group 1 PAH patients in multiple clinical settings. Our results implicate contributions of genetic ancestry to differential survival in PAH.
ASCPT 2020 Annual Meeting
Dr. Jason H. Karnes presents on Big Drug Data: A Guide to Utilizing Electronic Health Records for Clinical Pharmacology Research in March at the 2020 ASCPT Annual Meeting
University of Minnesota Biennial Pharmacogenomics Conference
Dr. Jason H. Karnes presents on Evidence for Implementation of PGx for Hypersensitivity Reactions and Future Directions in June at the University of Minnesota Biennial Pharmacogenomics Conference
CyVerse Learning Institute - Foundations of Open Science Skills (FOSS) 2020
PhD Student, Jason B. Giles attends FOSS.
Foundational Open Science Skills (FOSS) is a novel, camp-style training designed to prepare principal investigators and their lab teams, both new and established, to meet the growing expectations of funding agencies, publishers, and research institutions for scientific reproducibility and data accessibility.
Precision Medicine and Pharmacogenomics P4 Conference 2020
The symposium brings together health care professionals and community members to discuss the current state of precision medicine in Arizona, opportunities for the future, and concerns to be addressed with the collection, utilization and storage of precision medicine data.
Event Tickets & Details
Video Highlights from 2019
New Clinical Study Launched
Check Eligibility Here
Warfarin is a commonly used blood thinner to treat and prevent blood clots. Correct warfarin dosing is important since over-dosing leads to bleeding and under-dosing leads to blood clots. In order to provide more accurate dosing, clinicians consider patient factors such as age, body size, diet, and other medications that interact with warfarin. In addition to these patient factors, genetic variation has been used to better predict a patient’s warfarin dose. However, these predictions still have room for improvement. Through collection of multiple stool samples, this study aims to explore the effect of human gut bacteria on warfarin dose. We predict that the addition of information regarding a patient’s gut bacteria will improve warfarin dose prediction.
